Stock of the Day

December 15, 2021

Insmed (INSM)

$99.21
+$1.42 (+1.5%)
Market Cap: $21.36B

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Today's Trend

Insmed, Inc. (NASDAQ: INSM) is benefiting from favorable analyst expectations and investor attention around its expanding respiratory drug pipeline. The company’s stock remains well below the cited analyst price targets, while several upcoming clinical presentations could provide additional catalysts.

  • HC Wainwright raised its 2026 EPS forecast to a loss of $1.26 per share from a projected loss of $1.86, and improved its quarterly estimates for the third and fourth quarters. The firm reiterated its Buy rating and $220 price target, signaling expectations for better-than-previously-anticipated financial performance. HC Wainwright raises Insmed earnings estimates
  • Insmed is highlighting its global Phase 3 PALM program for treprostinil palmitil inhalation powder (TPIP) at CHEST 2026. The program includes four pivotal studies spanning pulmonary arterial hypertension, interstitial lung disease, progressive pulmonary fibrosis and idiopathic pulmonary fibrosis, broadening the potential commercial opportunity for TPIP. Insmed presents PALM Phase 3 program at CHEST 2026
  • New respiratory data from the TPIP, ASPEN and ENCORE programs will be presented at CHEST 2026 and IDWeek 2026. The disclosures could strengthen confidence in Insmed’s pipeline, including TPIP’s potential in PAH and PH-ILD and treatment strategies for MAC lung disease. Insmed respiratory data presentations
  • UBS maintained its $172 price target for Insmed. The target remains substantially above the recent trading level, but the lack of an upgrade or target increase makes this more of a reaffirmation than a new catalyst. UBS maintains Insmed price target
← Previous Stock of the DayNext Stock of the Day →

Recent News